Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

[Introduction]: The validated 40-gene expression profile (40-GEP) test independently stratifies risk of regional or distant metastasis for cutaneous squamous cell carcinoma (cSCC) tumors with high-risk clinicopathologic features. This study evaluated the stratification of risk by the 40-GEP test in...

Descripción completa

Detalles Bibliográficos
Autores: Wysong, Ashley, Somani, Ally-Khan, Ibrahim, Sherrif F., Cañueto, Javier, Fitzgerald, Alison L., Siegel, Jennifer J., Prasai, Anesh, Goldberg, Matthew S., Farberg, Aaron S., Regula, Christie, Bar, Anna, Kasprzak, Julia, Brodland, David G., Koyfman, Shlomo A., Arron, Sarah T.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/364791
Acceso en línea:http://hdl.handle.net/10261/364791
Access Level:acceso abierto
Palabra clave:40-GEP
Cutaneous squamous cell carcinoma
Metastasis
Prognostic
Risk assessment
id ES_ece0be6d439d17ab1ceee9c620e46e3d
oai_identifier_str oai:digital.csic.es:10261/364791
network_acronym_str ES
network_name_str España
repository_id_str
spelling Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) PatientsWysong, AshleySomani, Ally-KhanIbrahim, Sherrif F.Cañueto, JavierFitzgerald, Alison L.Siegel, Jennifer J.Prasai, AneshGoldberg, Matthew S.Farberg, Aaron S.Regula, ChristieBar, AnnaKasprzak, JuliaBrodland, David G.Koyfman, Shlomo A.Arron, Sarah T.40-GEPCutaneous squamous cell carcinomaMetastasisPrognosticRisk assessment[Introduction]: The validated 40-gene expression profile (40-GEP) test independently stratifies risk of regional or distant metastasis for cutaneous squamous cell carcinoma (cSCC) tumors with high-risk clinicopathologic features. This study evaluated the stratification of risk by the 40-GEP test in a large cohort of tumors with one or more high-risk factors and in clinically relevant subgroups, including tumors within National Comprehensive Cancer Network (NCCN) high- and very-high-risk groups, lower-stage BWH T1 and T2a tumors, and patients > 65 years old. [Methods]: This multicenter (n = 58) performance study of the 40-GEP included 897 patients. Kaplan-Meier analyses were performed to assess risk stratification profiles for 40-GEP Class 1 (low), Class 2A (higher) and Class 2B (highest) risk groups, while nested Cox regression models were used to compare risk prediction of clinicopathologic risk classification systems versus risk classification systems in combination with 40-GEP. [Results]: Patients classified as 40-GEP Class 1, Class 2A, or Class 2B had significantly different metastatic risk profiles (p < 0.0001). Integrating 40-GEP results into models with individual clinicopathologic risk factors or risk classification systems (Brigham and Women’s Hospital, American Joint Committee on Cancer Staging Manual, 8th Edition) and NCCN demonstrated significant improvement in accuracy for prediction of metastatic events (ANOVA for model deviance, p < 0.0001 for all models). [Conclusion]: The 40-GEP test demonstrates accurate, independent, clinically actionable stratification of metastatic risk and improves predictive accuracy when integrated into risk classification systems. The improved accuracy of risk assessment when including tumor biology via the 40-GEP test ensures more risk-aligned, personalized patient management decisions.This study was supported by Castle Biosciences, Inc. (CBI), which provided funding for tissue and clinical data retrieval to contributing centers and the journal’s Rapid Service Fee.Peer reviewedSpringer NatureCastle BiosciencesConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/364791reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1007/s13555-024-01111-5Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3647912026-05-22T06:33:51Z
dc.title.none.fl_str_mv Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
title Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
spellingShingle Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
Wysong, Ashley
40-GEP
Cutaneous squamous cell carcinoma
Metastasis
Prognostic
Risk assessment
title_short Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
title_full Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
title_fullStr Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
title_full_unstemmed Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
title_sort Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
dc.creator.none.fl_str_mv Wysong, Ashley
Somani, Ally-Khan
Ibrahim, Sherrif F.
Cañueto, Javier
Fitzgerald, Alison L.
Siegel, Jennifer J.
Prasai, Anesh
Goldberg, Matthew S.
Farberg, Aaron S.
Regula, Christie
Bar, Anna
Kasprzak, Julia
Brodland, David G.
Koyfman, Shlomo A.
Arron, Sarah T.
author Wysong, Ashley
author_facet Wysong, Ashley
Somani, Ally-Khan
Ibrahim, Sherrif F.
Cañueto, Javier
Fitzgerald, Alison L.
Siegel, Jennifer J.
Prasai, Anesh
Goldberg, Matthew S.
Farberg, Aaron S.
Regula, Christie
Bar, Anna
Kasprzak, Julia
Brodland, David G.
Koyfman, Shlomo A.
Arron, Sarah T.
author_role author
author2 Somani, Ally-Khan
Ibrahim, Sherrif F.
Cañueto, Javier
Fitzgerald, Alison L.
Siegel, Jennifer J.
Prasai, Anesh
Goldberg, Matthew S.
Farberg, Aaron S.
Regula, Christie
Bar, Anna
Kasprzak, Julia
Brodland, David G.
Koyfman, Shlomo A.
Arron, Sarah T.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Castle Biosciences
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv 40-GEP
Cutaneous squamous cell carcinoma
Metastasis
Prognostic
Risk assessment
topic 40-GEP
Cutaneous squamous cell carcinoma
Metastasis
Prognostic
Risk assessment
description [Introduction]: The validated 40-gene expression profile (40-GEP) test independently stratifies risk of regional or distant metastasis for cutaneous squamous cell carcinoma (cSCC) tumors with high-risk clinicopathologic features. This study evaluated the stratification of risk by the 40-GEP test in a large cohort of tumors with one or more high-risk factors and in clinically relevant subgroups, including tumors within National Comprehensive Cancer Network (NCCN) high- and very-high-risk groups, lower-stage BWH T1 and T2a tumors, and patients > 65 years old. [Methods]: This multicenter (n = 58) performance study of the 40-GEP included 897 patients. Kaplan-Meier analyses were performed to assess risk stratification profiles for 40-GEP Class 1 (low), Class 2A (higher) and Class 2B (highest) risk groups, while nested Cox regression models were used to compare risk prediction of clinicopathologic risk classification systems versus risk classification systems in combination with 40-GEP. [Results]: Patients classified as 40-GEP Class 1, Class 2A, or Class 2B had significantly different metastatic risk profiles (p < 0.0001). Integrating 40-GEP results into models with individual clinicopathologic risk factors or risk classification systems (Brigham and Women’s Hospital, American Joint Committee on Cancer Staging Manual, 8th Edition) and NCCN demonstrated significant improvement in accuracy for prediction of metastatic events (ANOVA for model deviance, p < 0.0001 for all models). [Conclusion]: The 40-GEP test demonstrates accurate, independent, clinically actionable stratification of metastatic risk and improves predictive accuracy when integrated into risk classification systems. The improved accuracy of risk assessment when including tumor biology via the 40-GEP test ensures more risk-aligned, personalized patient management decisions.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/364791
url http://hdl.handle.net/10261/364791
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1007/s13555-024-01111-5
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423378106941440
score 15,812455

Similares en LA Referencia